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1. Introduction 
There is a nosological dilemma when it comes to classifying what comprises a 
neurodegenerative disease (NDD). Degeneration – purely speaking – is to go from a higher 
to a lower level of functioning; it is deterioration from normalcy. Neurons are the functional 
elements of the nervous system. Then degeneration of the nervous system consists of a 
decrease or loss in the function of neurons. Not necessarily an atrophy, which consists of the 
death of a particular population of neurons. Clinically, NDD are comprised of progressive 
dementias, progressive ataxias, disorders in posture and movement, muscle weakness, and 
progressive blindness. The common characteristic in all of these pathologies is their 
chronicity. Each and every one of the aforementioned diseases consists of a chronic 
progression towards the loss of a particular function. However, this definition does not 
include a limit on temporality. Nosologically speaking neurodegeneration could include 
several other pathologies from an acute time frame. NDD can further be divided into an 
acute and chronic classification. Chronic diseases such as: amyotrophic lateral sclerosis 
(ALS), Alzheimer disease (AD) and Parkinson disease (PD) were the common conception of 
NDD. The latter was sustained until acute traumatic injuries to the central nervous system 
(CNS) were found to cause generalized inflammation and other phenomena that lead to 
degeneration. Examples of CNS injury that cause this secondary degeneration are: global or 
focal cerebral ischemia (stroke), spinal cord injury (SCI), and traumatic brain injury (TBI). 
The similarities in neurodegenerative processes between these and chronic NDD allows us 
to classify them within acute NDD. Neurodegeneration previously consisted of progressive 
atrophic disorders but has now expanded into the study of all pathophysiological processes 
that deteriorate the CNS. As a whole, NDD are the cause of many deaths around the world. 
In the US, stroke, traumatic injuries (such as: SCI and TBI), AD, and PD are within the top 15 
causes of mortality, averaging 350,000 deaths per year (Xu et al., 2007). Although NDD have 
an elevated mortality their greatest impact is on morbidity, affecting 50 million Americans 
each year and generating a large amount of federal spending (Brown et al., 2005). Every year 
$144 billion USD are spent on AD alone, and that is excluding the spending required for the 
other 600 neurological disorders that have been described (Alzheimer’s Association, 2010; 
Meek et al., 1998). The elevated prevalence and incidence require a large initiative to 
research the hallmarks of these diseases. Until now, our understanding of NDD is quite  
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complex but there is still a lot to uncover. Research is normally directed towards the NDD 
with the most impact on society such as: ALS, AD and PD. Due to the increased availability 
of information on the previous diseases this chapter will only discuss these diseases within 
the chronic NDD section. In order to find treatment opportunities for each one of these 
diseases we must first understand the basic pathophysiology. ALS is a progressive 
degeneration of upper and lower motor neurons in the brain and spinal cord. This atrophy 
eliminates the brain’s control over muscle movements and causes them to weaken and 
become paralyzed. Progressive muscular paralysis causes the inability to move, swallow, 
and eventually, breathe (Angelov et al., 2003). AD is a progressive disorder characterized by 
memory loss and severe cognitive decline. This degeneration is caused by excessive 
accumulations of extracellular amyloid beta peptide, which forms plaques in the 
hippocampus and cerebral cortex, leading to neuronal death (Frenkel et al., 2005; Butovsky 
et al., 2006). PD is a chronic progressive disease characterized by motor symptoms (tremor, 
rigidity and bradykinesia) and nonmotor symptoms (e.g. autonomic, mood and cognitive). 
These clinical hallmarks are attributed to the degeneration of nigrostraital dopaminergic 
neurons and other structures in the brainstem, cortex, and subcortex (Laurie et al., 2007). 
Multiple sclerosis (MS) is an inflammatory autoimmune CNS demyelinating disease that is 
thought to be perpetrated by myelin-reactive lymphocytes. Demyelination of the CNS 
causes the loss of function of the affected tract (Stuve et al., 2006). MS is considered an 
autoimmune disease and not a NDD because there is no direct neuronal death only 
demyelination. The nosology of NDD excludes MS from our study but it still shares very 
similar immune pathophysiology and most of the therapies mentioned are derived or 
designed for use in MS. The inflammatory component of acute injury to the CNS provided 
new insight into the autoimmune response propagated after a CNS insult. These findings 
gave immune cells a crucial role in the protection and regeneration of the injured CNS, as 
well as a role in chronic progressive NDD. Further insight into the immunological 
component of neurodegenerative diseases provides us with new mechanisms where we are  
able to intervene in order to resolve these disorders. One of these mechanisms is protective 
autoimmunity (PA). PA is a new concept where autoreactive mechanisms are being 
modulated in order to promote neuroprotection. Dr. Michal Schwartz from the Weizmann 
Institute of Science in Israel originally conceived this concept. Infiltration of immune cells 
after CNS injury was traditionally regarded as pathological. This view was based on the fact 
that immune cell-infiltration has been exclusively identified with inflammation, and that 
inflammation is generally harmful to the injured CNS. However, recent studies indicate that 
a well-controlled innate and adaptive immune response is essential for the repair of the 
injured tissue. These results brought about research into immunomodulatory therapies in 
several NDD. In acute NDD and MS, recent findings have suggested that the inflammatory 
response is strongly modulated by an autoimmune reaction directed against neural 
constituents, specifically against myelin basic protein (MBP), one of the most abundant and 
immunogenic proteins in the CNS (Butovsky et al., 2001; Ibarra et al., 2003; Popovich et al., 
1996; Sospedra & Martin, 2005). Dr. Schwartz started to modulate the action of myelin-
specific autoreactive lymphocytes by immunizing with MBP. This strategy improved tissue 
preservation, neuronal survival and motor recovery after acute SCI (Hauben et al., 2000a; 
Hauben et al., 2000b). PA also proved to be a T cell-dependent response that is genetically 
determined (Kipnis et al., 2001) and triggered as a physiological response to CNS trauma 
(Yoles et al., 2001). However, immunizing animals with self-antigens (i.e. MBP) induced an 
autoimmune disease known as experimental autoimmune encephalomyelitis (EAE, animal 
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model of MS). Therefore, a different way of eliciting PA had to be obtained in order to 
prevent this complication. Studies suggested that immunizing with a weaker version of the 
self-antigen could solve the problem, these type of antigens became known as altered 
peptide ligands (APL). Vaccinating with APL would generate PA without degenerative 
autoimmunity. In the study of NDD, APL were derived from neural constituents and were 
therefore coined under the term neural-derived peptides (NDP). The success in the 
development of these immunomodulatory peptides has inspired a lot of research into their 
possible therapeutic applications in both chronic and acute NDD. These applications will be 
described in detail throughout this chapter. 
2. Role of immune cells and their potential therapeutic effect 
The CNS has long been considered to be an immunologically privileged location. The blood-
brain barrier (BBB) was thought to maintain blood-borne cells of both the innate and 
adaptive immune system out of the CNS. This hypothesis assumed that microglia were the 
only innate immune cells of the CNS. During damage, microglia became activated and 
functioned as destructive inflammatory cells indistinguishable from infiltrating 
macrophages. Immune cells were thought to contribute to the increase in tissue damage 
during CNS disease (Bethea et al., 1998; Blight, 1992; Dusart et al., 1994; Popovich et al., 
1997). The idea was supported by the following: i) CNS trauma activates T lymphocytes 
against neural constituents, and ii) the passive transfer of myelin autoreactive T cells caused 
EAE in previously healthy rats (Popovich et al., 1996). The notion was sustained in such a 
way that the complete inhibition of these responses was proposed as a potential therapeutic 
intervention, and remains to this day as the predominant clinical approach (Lopez-Vales et 
al., 2005; Popovich et al., 1999). However, it is now clear that these cells have a pivotal role 
in CNS repair (Hammarberg et al., 2000; Hashimoto et al., 2007; Hendrix & Nitsch, 2007; 
Moalem et al., 1999; Rapalino et al., 1998; Turrin & Rivest, 2006; Yin et al., 2003). In the 
healthy CNS the microglia is in a resting state where its morphology consists of a small cell 
soma and numerous branching processes, known as resting/ramified state. The 
ramifications are dynamic structures that enable the cell to sample and monitor its 
microenvironment (Nimmerjahn et al., 2005; Raivich, 2005). Resting microglia express CD45 
(leukocyte common antigen), CD14, and CD11b/CD18 (Kreutzberg, 1996). Under duress, 
microglial expression patterns are modified from a monitoring role to one of protection and 
repair. Microglia begin to express key surface receptors such as: CD1, lymphocyte function-
associated antigen 1 (LFA-1), intracellular adhesion molecule 1 (ICAM-1), and vascular cell 
adhesion molecule 1 (VCAM-1). Besides changing their surface receptor repertoire they 
begin to secrete: inflammatory cytokines such as TNFα and interleukins IL-1┚ and IL-6, 
chemokines like macrophage inflammatory protein (MIP-1α), monocyte chemoattractant 
protein (MCP-1), and interferon inducible protein 10 (IP-10). This change in 
microenvironment changes the resting/ramified state of the microglia into an 
amoeboid/phagocytic state. The activated state of microglia has beneficial functions during 
NDD such as: scavenging neurotoxins, removing cellular debris, and the secretion of trophic 
factors that promote neuronal survival (Frank-Cannon et al., 2009). During CNS injury, if 
microglia come in contact with products of the adaptive immune response such as 
interferon gamma (IFN-┛) and IL-4 it will acquire a phenotype that has antigen presenting 
cell (APC)-like qualities. This phenotype expresses major histocompatibility complex II 
(MHC-II) and B 7.2 receptors, giving it the ability to interact with elements of the adaptive 
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immune response. As an APC, microglia can hold dialogue with T cells and are capable of 
releasing neurotrophic factors (BDNF, NT-3, NGF) and scavenging toxic neurotransmitters 
and reactive oxygen species (ROS) that endanger the tissue (Li et al., 2007; Schwartz et al., 
2003). However, the chronic and uncontrolled activation of microglia increases the 
permeability of the BBB and elevates the amount of infiltrating blood-borne immune cells 
(Schmid et al., 2009). This promotes the activation of microglial cells into a destructive 
phenotype characterized by the production of high levels of nitric oxide (NO, a potent free 
radical), as well as TNFα, and cyclooxygenase 2 (COX2) (Franciosi et al., 2005; Lee et al., 
2007; Shaked et al., 2004). In this phenotype microglia express low amounts of MHC-II and 
are thus incapable of communicating with the adaptive immune system, an important 
condition to promote neuroprotection (Schwartz et al., 2003; Shaked et al., 2004). In addition, 
T lymphocytes are recruited in small amounts and very late. The lack of T cell-mediated 
activation of microglia results in an uncoordinated release of additional pro-inflammatory 
cytokines, exacerbating the damage (Bethea et al., 1999; Lopez-Vales et al., 2006; Pan et al., 
2003; Resnick et al., 1998; Schwartz et al., 2003; Vanegas & Schaible, 2001). The best way to 
elicit a T cell-mediated activation of microglial cells is through neural autoreactive T cells. 
This assures that T cells arrive to the CNS and activate microglia into their protective 
phenotype propagating the beneficial effects mentioned above (Figure 1). PA has proven to 
yield clinical improvements in the treatment of several NDD. 
 
 
Fig. 1. T cell recruitment into the injured CNS 
Left panel: An uncontrolled response where T cells are recruited very late allows the 
activation of microglia into a destructive phenotype. This is characterized by the release of 
nitric oxide (NO) and proinflammatory molecules like tumor necrosis factor alfa (TNF-α) 
and cyclooxygenase-2 (COX2). Under these circumstances, T cells intensify the inflammatory 
response and exacerbate neurodegeneration. Right panel: When the autoreactive response  
is elicited by immunizing with NDP there is an earlier and larger arrival of T cells. With  
this approach, microglial cells undergo a T cell-mediated activation into a protective 
phenotype. This regulated activation releases molecules that promote neuroprotection and  
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neuroregeneration such as: neurotrophins (NT), nerve growth factor (NGF), and insulin-like 
growth factor 1 (IGF-1). The early arrival of T cells due to immunization with NDP regulates 
the response so that we can obtain the benefits and not the detriments of the immune 
response.  
3. Modulation of the immune response using neural-derived peptides 
Immunomodulation is an idea from the past that looks more promising than ever. It is a 
change in the body’s normal physiological immune response to a specific antigen. This 
modulation changes the way the immune system would normally respond to an event and 
replaces it with an alternate desired response. The modification of immune responses is 
different from agents that suppress the immune response (such as corticosteroids). 
Immunomodulation has already become a reality. For example, IFN-┛ is used in patients 
with chronic granulomatous disease (Farhoudi et al., 2003), IFN-┚ is used in patients with 
multiple sclerosis (Kumpfel et al., 2007), and IL-2 in patients with AIDS and metastatic 
melanoma (Davey et al., 1997; Terando et al., 2003). Aside from this, numerous vaccines use 
adjuvants to achieve the desired immune response (Partidos et al., 2004; Petrovsky & 
Aguilar, 2004). Modulation of the immune response as a therapeutic strategy is a promising 
alternative for several diseases. PA allows us to speculate that it is better to modulate the 
immune response rather than eliminating it. In chronic NDD, patients require a competent 
immune response to fend off pathogens and evade complications due to infections. The 
ablation of the immune response is usually done with steroids or immunosuppressants, 
which severely affect the patient’s ability to initiate an adequate immune response. In the 
acute form of NDD the immune system is vital in the return to homeostasis. Immune cells 
extract cellular debris, reestablish blood flow, secrete neurotrophic factors and eliminate 
pathogens. All these beneficial effects are lost when the immune response is inhibited using 
immunosuppressant therapy. Accordingly, it seems only logical that the immune response 
is essential in NDD. In line with this, it is realistic to envision that the harmful effects exerted 
by immune cells could be reverted or changed to promote beneficial actions. In order to 
achieve this goal, it is crucial to avoid or at least diminish the activation of microglial cells by 
means of the classic pathway (destructive phenotype). For this purpose, an earlier and 
larger arrival of T cells to the site of injury should be promoted. The opportune and 
adequate arrival of these cells will favor the activation of microglia under the bases of a 
protective phenotype (Shaked et al., 2004). A simple way of making this possible is by 
immunizing with the same antigen that induces the autoreactive response: neural antigens. 
With this approach, an important number of microglial cells will acquire the protective 
phenotype and will then release molecules that instead of increasing damage will promote 
neuroprotection. Thus, we will obtain the benefits and not the detriments of this immune 
response. The present strategy proposes the modulation of the immunological response  
by boosting an autoreactive reaction. This could be a bit conflicting for general 
understanding since it is common to associate autoimmunity with disease. However, at 
present, it is very clear that autoimmunity is a physiological phenomenon perfectly 
compatible with homeostasis (Schwartz & Cohen, 2000). Furthermore, autoimmunity has 
been proposed as a useful and beneficial event (Hauben et al., 2005). Therefore, PA is a 
protective strategy where autoimmunity is the main player in providing beneficial effects 
during CNS injury. 
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4. Modulation of protective autoimmunity with no risk of autoimmune disease 
As it was mentioned before, the possibility of inducing an autoimmune disease after 
vaccination with neural constituents is perhaps the main complication of this therapy. In 
order to solve this issue, immunizations are done with NDP. NDP are analogs of 
immunogenic epitopes with one (or a few) substitution(s) at specific amino acid positions of 
neural peptides (NP). The variation between the amino acid sequence is essential for contact 
with the T cell receptor (TCR) during antigen processing. This variation allows them to 
compete for TCR binding and to interfere with the necessary sequence of events required for 
T cell activation. The interference caused by NDP in TCR antigen recognition could affect T 
cell differentiation or induce a state of anergy (Nel & Slaughter, 2002). The specificity and 
avidity of the TCR with its ligand is determined by the primary sequence of the antigenic 
peptide. That particular sequence affects its binding to the complementary-determining 
regions of the TCR and the peptide-binding groove of the HLA molecule (Garboczi et al., 
1996). A small variation in amino acid sequence can alter its ability to interact with either the 
MHC-II or TCR receptor molecule. This competition thereby converts an agonist peptide 
into a partial agonist or even an antagonist (Jameson & Bevan, 1995). Agonist peptides 
engage in high-affinity interactions with the TCR and induce a robust T cell response; 
whereas partial agonists or antagonists engage in lower affinity interactions that lead to 
altered or inhibitory responses (Jameson & Bevan, 1995; Kersh & Allen, 1996). Stimulation of 
naïve CD4+ T cells with an agonist peptide induces sufficient assembly of signaling 
complexes to allow activation of the IL-2 promoter and support a Th1 differentiation 
pathway. In contrast, the signals generated by APL activation are generally insufficient to 
induce IL-2 synthesis and therefore will not cause activation. That lack of IL-2 production 
might induce an anergic state or a skewing of the Th1/Th2 differentiation (Nel & Slaughter, 
2002). Some APL are already being explored for neurological diseases (Figure 2). These 
peptides are derived from MBP-encephalitogenic epitopes. A group of them (G91, A96 and 
A91) have already been tested in animal models (Hauben et al., 2001). Importantly, 
immunized animals did not present clinical signs of EAE. A91 is a peptide derived from 
MBP (sequence 87-99), where the lysine residue at position 91 is replaced for alanine. This 
NDP cross-reacts with the original encephalitogenic epitope of MBP but it activates weak 
self-reactive T cells thus inducing autoimmunity without developing EAE. Immunizing 
with A91 inhibits EAE but neither causes anergy nor clonal deletion (Gaur et al., 1997). 
During antigenic presentation, A91 works as a partial agonist that instead of inducing a Th1 
response promotes a Th2 differentiation pathway. This preference for the Th2 phenotype 
may be responsible for the elimination of the Th1-dependent response observed in EAE. 
Studies also indicate that post-injury injection of bone marrow-derived dendritic cells 
pulsed with A91, induce the same significant beneficial effects (Hauben et al., 2003). This 
indicates that the APC properties of the dendritic cell are enough to activate anti-A91 CD4+ 
T cells that are responsible for the elevated neuroprotection. To further support the use of 
immunomodulatory NDP, our laboratory examined the effects of combining immunizations 
with A91 and methylprednisolone (MP). The use of corticosteroids, such as MP, is the only 
therapeutic agent currently available for the treatment of a variety of NDD, primarily CNS 
trauma. In our study, a high dose of MP was administered together with an A91 
immunization after SCI. As expected, MP eliminated the beneficial effects of A91. 
Nevertheless, when vaccination with A91 was delayed for 48 h after injury, there was no 
interference with its effect by the anti-inflammatory action of MP injected immediately after  
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Fig. 2. Immunization with NDP causes repair and protection of the injured CNS Immunizing 
with NDP causes a peculiar adaptive immune response. The similarity of NDP with neural 
peptides (NP) causes T cell activation to deviate towards a Th2 phenotype. These NDP-
reactive T cells are released into systemic blood flow where they can hone towards the site 
of injury. Once these autoreactive T cells infiltrate into the CNS, they come in contact with 
glial cells and activate microglia into a neuroprotective phenotype. Activated microglia 
function as antigen presenting cells (APC) and present NP to anti-NDP Th2 cells producing 
anti-inflammatory cytokines like interleukin- 4 and -10 (IL-4, IL-10) and transforming 
growth factor beta (TGF-┚). This T cell-mediated anti-inflammatory effect further 
ameliorates the degenerative phenomena developed after CNS insult. These cells have also 
been shown to produce neurotrophic factors implicated in neuroregeneration like 
neurotrophin-3 (NT-3) and brain-derived neurotrophic factor (BDNF) 
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SCI (Ibarra et al., 2004). This finding suggests that vaccination with A91 is neuroprotective 
even if administered 48 h after injury, and that the effect of MP over the immune system is 
transient and does not interfere with later therapy even if that treatment is immune related. 
These results offer another interesting benefit of NDP-induced PA, and that is the clinical 
plausibility of these therapies. In the clinical setting, CNS trauma and pathology is 
diagnosed long after the moment of incidence. NDP-induced PA is functional even when 
administered 48 h after the development of NDD and works as an adjuvant in traditional 
clinical treatment protocols (MP administration post-CNS trauma). It appears that the 
beneficial effect of the vaccination with A91 will not necessarily be neutralized by 
concomitant treatment with MP. It is worth mentioning that one of the most prevailing 
adverse effects observed after NDP immunization is immediate-type hypersensitivity 
reactions. This undesirable effect is generally associated with the immune deviation toward 
Th2 phenotype. These observations should stimulate further research into which patients 
are most likely to benefit from this therapy. Taking into consideration all of the data, 
therapeutic vaccination with NDP appears to be a promising strategy that could be adapted 
for treatment in several NDD. 
5. Effect of immunizing with neural-derived peptides  
In the study of neuroprotection, the term autoreactivity is immediately associated with 
increased cell death, inhibition of neuroprotective mechanisms and a worse clinical outcome 
after CNS injury. However, our understanding of the immune system’s role in the 
pathological CNS has changed drastically in the last couple of years. The old school of 
thought indicated that the immune response was responsible for the exacerbation of 
neurodestructive phenomenon, so the first line of defense was immunosuppression. The 
recent findings of PA suggested that the immune response was not only needed after an 
insult to the CNS but it also had a beneficial neuroprotective role in most NDD. This radical 
change in information forces us to reevaluate the existing treatment protocols for all NDD. If 
PA is present in a number of CNS diseases then the use of NDP immunizations is a 
reasonable treatment option. The use of NDP-induced PA results in the generation of a 
prevalent Th2 phenotype. These cell types have shown to have the most overwhelming 
neuroprotective effect in the CNS. The influential roles that these cells have on the outcome 
of disease have made them the goal of therapy development. The increase in Th2-inducing 
interventions has been studied in ALS, AD, PD, SCI, TBI, and stroke; it has even been 
proposed as a treatment for neurodevelopmental disorders such as Rett syndrome (Ben-
Zeev et al., 2011). There are many different approaches to the induction of autoreactive Th2 
lymphocytes some of these are: glatiramer acetate (GA, Coplymer-1, Cop-1, Copaxone), A91, 
poly-YE, p472 (Nogo-A-derived peptide). However, the only FDA-approved use of NDP-
induced PA is GA under the brand name Copaxone for the treatment of MS. GA, also 
known as Cop-1, is the most studied of all APL-based therapies. Cop-1 is a synthetic 
polypeptide consisting of the amino acids tyrosine, glutamate, alanine and lysine that shows 
cross-reactivity with MBP (Schori et al., 2001; Kipnis & Schwartz, 2002). While the exact 
mechanism of Cop-1 is still not clearly elucidated, there is reason to believe that it induces 
Th2 differentiation, which later goes on to mediate neuroprotection (Aharoni et al., 2003; 
Aharoni et al., 2000). Although Th2 induction is the primary effect, immunization with Cop-
1 also results in a Th1 cell deviation. This effect may seem paradoxical in nature but these 
pro-inflammatory Th1 cells are responsible for a sustained release of BDNF, NT-3, and NT-4 
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(Ziemssen, 2002, 2005). This Th1-mediated effect also induces astrocyte and neuronal 
production of these neurotrophic factors through a bystander effect (Aharoni et al., 2005). 
However, the effect of Cop-1 is not only mediated by its direct effect on CD4+ lymphocytes 
but also of its effect on APC, especially dendritic cells (DC). A recent study demonstrated 
that Cop-1 induced a Th2 response by modulating the APC function of DC. They 
demonstrated that DC exposed to Cop-1 during maturation had an impaired capacity of 
secreting IL-17p70 (the main Th1-polarizing cytokine). This effect resulted in the induction 
of a population with an increased frequency of effector Th2 cells that secreted IL-4 (Sanna et 
al., 2006; Vieira et al., 2003). Although the main components of NDP-induced PA are 
superficially understood, more research initiatives should be taken to better understand the 
therapeutic potential of these peptides. Most of the studies published use Cop-1 as the NDP, 
but the use of alternate peptide sequences such as A91 must be better understood. 
Nonetheless, there should be a constant effort to develop shorter, cheaper and more 
efficacious peptide sequences so that the true potential of NDP can be unlocked. Few studies 
have been conducted on the use of NDP in NDD. 
5.1 Chronic neurodegenerative diseases 
5.1.1 Amyotrophic lateral sclerosis  
There have been many attempts to halt the progression of ALS by blocking different 
mediators of cytotoxicity (Ludolph et al., 2000). Because not all ALS patients have the 
defective SOD1 gene, motor neuron death is taken as the hallmark of disease because it is 
common to all cases of ALS. The animal model of ALS is acute peripheral nerve axotomy 
(Liu & Martin, 2001; Martin et al., 2000). The only drug currently used to slow down the 
progression of ALS is riluzole. Riluzole blocks the release of the excitatory neurotransmitter 
glutamate that can be toxic in elevated concentrations and is fundamental to ALS 
pathophysiology (Doble & Kennel, 2000; Meininger et al., 2000). In this study conducted by 
Angelov et al., mice treated with Cop-1 (using a different regimen than MS) show more 
motor neuron survival in the acute and chronic phases of ALS (Angelov et al., 2003). In the 
study, mice were subjected to a unilateral facial nerve axotomy. They were then immunized 
with Cop-1 and assessed. The results showed that vaccination with Cop-1 protected against 
motor neuron death induced after facial nerve axotomy. Transection of the facial nerve in 
the adult mouse is known to cause an easily visible late degeneration of axotomized motor 
neurons (Sendtner et al., 1996). Eight weeks after axotomy, mice immunized with Cop-1 had 
significantly larger numbers of motor neurons compared to PBS-immunized controls. 
Studies also indicated that immunization with Cop-1 preserved the activity of axotomized 
motor neurons. The study concluded that there was an elevated preservation of facial nerve 
motor neurons but the next step was to confirm that these were still functional. Using 
biometrical analysis of the mice’s whisking patterns they found that Cop-1-treated animals 
exhibited significantly better facial nerve functionality than controls. The previous results 
demonstrated that Cop-1-immunized ALS mice benefited from improved motor neuron 
survival and the preservation of their function after facial nerve axotomy. A mice strain that 
expresses human mutant SOD1 gene develops a motor disease that closely resembles 
human ALS. The loss of motor function eventually causes death because of the lack of 
muscular respiratory control. Angelov et al. concluded that treatment with Cop-1 
immunizations resulted in an increased survival of the ALS mice. Immunizations with Cop-
1 proved to be an adequate and efficacious therapy in an animal model of ALS. A small 
phase II study was held in human patients with ALS that finished with inconclusive results.  
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Most patients demonstrated adverse reactions at the site of immunization and elevated 
lymphocyte proliferation. Although the results showed promise, efforts must be taken to 
increase the sample size and scrutinize the possible mechanisms through which Cop-1 
exerts its protective effects (Gordon et al., 2006). These small but conclusive examples of 
NDP-induced PA in ALS provide us with enough proof to understand the possible 
therapeutic advantages. The study of Cop-1 in ALS is still in its beginning and should 
therefore be a priority in the coming years for NDD researchers. The maximal benefits of PA 
in ALS have not yet been achieved. 
5.1.2 Alzheimer disease  
Previous studies proved that immunotherapy in AD via amyloid beta (A┚) antibodies 
reduced the levels of A┚ plaques in transgenic mice. However, a human trial with A┚ 
antibodies caused severe adverse reactions in the form of meningoencephalitis (Nicoll et al., 
2003; Orgogozo et al., 2003). A study done by Frenkel et al. postulated that 
meningoencephalitis was very similar to EAE. They decided to test if amyloid precursor 
protein-transgenic (APP-Tg) mice were more susceptible to develop EAE. They concluded 
that EAE lowered the levels of A┚ in APP-Tg mice using antibody-independent 
mechanisms. As a follow-up they decided to see if they could achieve the low A┚ levels 
without causing EAE. GA or Cop-1 was an FDA-approved treatment for relapsing-remitting 
MS and was known to cause an autoreactive response without developing EAE. They were 
able to reproduce the amyloid load achieved in EAE using immunization with GA (Frenkel 
et al., 2005). Butovsky et al performed a more directed study, towards the analysis of PA in 
AD. This work found that A┚ activated microglia supports neurogenesis when stimulated 
by IL-4. This means that a Th2 phenotype will result in the overexpression of IL-4 and 
increased neurogenesis after microglial activation with A┚. Vaccination with autoreactive T 
cells besides aiding in neurogenesis helped in the elimination of the A┚ plaque in APP-Tg 
mice. The increase in neurogenesis and the removal of the A┚ plaques resulted in the 
counteraction of the cognitive decline normally seen in AD (Butovsky et al., 2006). The 
vaccination with NDP has proven to be of paramount importance in the treatment of yet 
another NDD. This data is also an indicator of the urgency with which these therapies 
should be developed, standardized, and translated into clinical trials where they can bear 
fruits to human disease. 
5.1.3 Parkinson disease  
Immunological studies in PD are controversial. The animal model is 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) intoxication (Benner et al., 2004; Laurie et al., 2006). This 
intoxication depletes dopaminergic neurons in the substantia nigra pars compacta (SNpc), 
simulating PD. The complication arises because MPTP toxicity also destroys the animal’s 
immune system, causing significant changes in spleen size and diminished numbers of 
CD3+ T cells 7 days after intoxication (Benner et al., 2004). The alterations in normal immune 
response impede the researcher’s ability to analyze the role of the immune system in PD. 
However, researchers bypass this complication by cell subset replacements. The use of NDP 
in PD has been briefly evaluated by several studies from the same laboratory. All studies use 
the MPTP toxicity model of PD and use adoptive transfer of T cells from Cop-1-immunized 
mice. In the first study of Benner et al. Cop-1-immunity was found to confer dopaminergic 
neuroprotection after MPTP intoxication. Animals that received the adoptive transfer of 
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Cop-1-reactive T cells exhibited a much smaller reduction in the number of SNpc 
dopaminergic neurons. For the functional analysis of dopaminergic circuits they quantified 
tyrosine hydroxylase (TH) density. The loss of TH density was significantly less in Cop-1-
immunized mice than in controls. Unfortunately, even in Cop-1 immunized mice, the loss of 
TH density was up to 72%. However, the conclusion was that Cop-1-reactive T cell passive 
immunization protected neuronal dopamine metabolism as well as structural neuronal 
elements and its projections. Complementary analysis stated that transferred lymphocytes 
were readily observed both in ventral midbrains and striata of MPTP mice. The study was 
also interested in evaluating microglial activation due to the fact that these cells are 
considered to be pathological in this NDD. To assess microglial activation they analyzed the 
Mac-1 gene using real time RT-PCR. Results showed that Cop-1 splenocytes are capable of 
attenuating MPTP-induced microglial reactions and in turn limiting their neurodestructive 
processes. In accordance to previously demonstrated concepts, the beneficial effects of Cop-
1 immunizations were T cell-dependent. Treatment with NDP also increased the expression 
of the neurotrophic factor GDNF. All results demonstrate the beneficial effects of 
immunizing with Cop-1 in PD (Benner et al., 2004). A similar study by Laurie et al. 
corroborated the results observed by Benner and co-workers. Although similar results were 
obtained, the latter was able to recollect new data. The study concluded that anti-Cop-1 
CD4+ T cell transfer into MPTP intoxicated mice exerted its reparative effects in a dose 
dependent manner. Also this study attributed the neuroprotection to a particular subset of T 
lymphocytes, CD4+ T cells. This further implicated T helper cells as the main player in PA. 
In order to support that PA is T cell-dependent, authors’ transplanted Cop-1 specific 
antibodies to MPTP intoxicated mice to see if this conferred neuroprotection, as expected the 
effects of Cop-1 are CD4+ T cell-dependent (Laurie et al., 2006). This study reiterates the 
outstanding potential that NDP-induced PA holds in the outcome of PD. Nonetheless, this 
topic deserves more investigation as to identify the effect of a normal functional immune 
system and not just the evaluation through substitution studies.  
5.2 Acute neurodegenerative diseases 
5.2.1 Cerebral ischemia  
Immunization with NDP has also proved to be beneficial in cases of focal and global 
cerebral ischemia. There have been several studies of oral and nasal tolerization with neural 
constituents (Becker et al., 1997; Frenkel et al., 2003); however, only a few have resorted to 
NDP. There are primarily two studies that analyze the effects of this Th2-induced response 
after middle cerebral artery occlusion. The first by Ziv et al. used poly-YE, a high molecular 
weight (22 to 45 kDa) copolymer that was shown to exert modulatory effects on the immune 
system (Cady et al., 2000; Vidovic & Matzinger, 1988). This peptide demonstrated abilities to 
downregulate regulatory T cell functions and allows effector T cell activation. The study 
showed that a single immunization with poly-YE produced long-lasting clinical and 
behavioral benefits, along with neuroprotection and increased neurogenesis, starting from 
the subacute phase. They also found that poly-YE was beneficial even when administered 24 
hours after occlusion. The effects of poly-YE immunization were long lasting as animals 
showed less residual impairment against controls even after 6 weeks. Histological analysis 
indicated that poly-YE attenuated cell loss in the hippocampus where PBS-treated rats 
showed large numbers of necrotic cells. The reduction in cell necrosis induced by poly-YE 
was so dramatic that the ipsilateral and contralateral sides were indistinguishable. 
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Immunization with poly-YE had a significant neuroprotective effect after stroke, but 
authors’ also wanted to evaluate its neuroregenerative properties. They found that poly-YE 
promotes neurogenesis after stroke as they saw an overall increase in the number of newly 
formed neurons in the dentate gyri of treated animals. The results presented in this study 
showed that the administrations of poly-YE as late as 24 hours after the induction of 
ischemic stroke greatly improved subsequent recovery. It had a positive effect on the 
neurological outcome of stroke, delayed degeneration, and enhanced the repair of damaged 
structures. Also, the therapeutic window (24 hours) seemed to be significantly wider than 
most of the current candidate therapies for stroke, giving it much more clinically 
translational value (Ziv et al., 2007). A separate study in our laboratory examined the effect 
of Cop-1 immunizations on the outcome of ischemic stroke, using the middle cerebral artery 
occlusion model. Results suggested that Cop-1 significantly improved the neurological 
outcome of animals after stroke. Histolopathological assessment also demonstrated a 
decrease in infarct size and infarct volume in Cop-1-treated animals (Ibarra et al., 2007). The 
results of both studies do not necessarily elucidate the mechanisms through which NDP-
induced PA exerts its protective effects in focal cerebral ischemia but they provide evidence 
of its neuroprotective, and even neuroregenerative, properties. These studies provide NDP-
induced PA with another consequential benefit, and that is the wide therapeutic window. 
Immunizations with NDP in the treatment of stroke require exhaustive research before they 
reach clinical trial potential but these preliminary results are an enormous step closer. 
5.2.2 Traumatic CNS injury 
Traumatic CNS injury can be broken down into two compartments: TBI and SCI. A study by 
Kipnis et al. found that immunizing with Cop-1 after traumatic brain injury had a better 
outcome on neurological and histological evaluations after injury (Kipnis et al., 2003). TBI 
triggers self-destructive processes, like other injuries to the CNS. Kipnis et al. studied mice 
with closed head injury and determined that the immune system plays a key role in the 
spontaneous recovery. The trauma-induced deficit was reduced, both functionally and 
anatomically, by post-traumatic vaccination with Cop-1. Several studies have been 
published on the use of NDP in SCI. Hauben et al. used immunization with a variety of 
myelin-associated peptides, including those derived from Nogo-A, can be used to evoke a T 
cell-mediated response that promotes recovery. They show that neuronal degeneration after 
incomplete spinal cord contusion in rats was substantially reduced, and hence recovery was 
significantly promoted, by posttraumatic immunization with Nogo-A-derived, p472 
(Hauben et al., 2001). Our laboratory has also demonstrated the beneficial effect of 
immunizing with NDP (A91) on motor recovery and neuronal survival after SCI (Martiñon 
et al., 2007). Furthermore, we have determined some of the mechanisms of action of NDP-
induced PA. In a recent study we found that immunization with Cop-1 and A91 exerted its 
neuroprotective effect through the inhibition of lipid peroxidation (LP). Animals were 
immunized with A91 seven days before injury. With the aim of inducing the functional 
elimination of CNS-specific T cells, animals were tolerized against SC-protein extract and 
thereafter subjected to a SCI. The lipid-soluble fluorescent products were used as an index of 
LP and were assessed after injury. Immunization with NDP reduced LP after SCI. 
Functional elimination of CNS-specific T cells avoided the beneficial effect induced by PA 
(Ibarra et al., 2010). A consequential study hypothesized that LP was caused by an 
unregulated production of ROS seen after CNS injury. The main ROS produced during the 
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secondary phase of damage after trauma is NO. When NO is produced in an unregulated 
fashion it can react with other free radicals such as superoxide anion and produce 
peroxynitrite a powerful neurotoxic substance. We determined that the decrease in lipid 
peroxidation was caused by an inhibition in the synthesis of NO after immunization with 
NDP after SCI (unpublished data). Our results supported our hypothesis and allowed us to 
corroborate the data with expression analysis. We used real time RT-PCR to also 
demonstrate a reduction in the expression of the enzyme implicated in post-injury synthesis 
of NO, the inducible form of nitric oxide synthase (iNOS) (unpublished data). By 
determining that A91 reactive T cells also secrete NT-3 and IL-4 after SCI, making them a 
Th2 phenotype, we further substantiate the PA hypothesis. Immunizing with NDP deviates 
the Th response down a Th2 pathway increasing the synthesis of molecules such as IL-4 and 
IL-10 and secretion of neurotrophic factors like NT-3. Finally, we have found that the 
severity of injury would determine the strength and the effect of the PA response 
(unpublished data). This new data adds more factors into the induction of an autoreactive 
response. Our study noticed that animals that sustained a non-complete injury to the spinal 
cord had an increased recovery when immunized with A91. These autoreactive T cells also 
secreted BDNF and had greater recognition for A91 in vitro. On the other hand, animals that  
sustained complete or severe SCI did not recover even after A91-immunization. 
Unexpectedly, these animals did not even possess a clonal response to A91, meaning they 
were not even able to recognize the antigen in vivo, even with an adjuvant. This indicates 
that animals that sustained a severe or complete injury to the spinal cord are severely 
immunosuppressed and may therefore not engage a true PA response (unpublished data). 
This data that has just surfaced indicates that the neuroimmunological components of CNS 
disease require much more research in order to elucidate this unknown mechanisms. Even 
further, we must continue to delve into this immunosuppression caused by severe injury. 
The study of the body’s physiology under duress shows us some of the mechanisms it 
possesses that could help in regenerating the CNS during disease. Immunization with NDP 
has proven to be an excellent therapeutical intervention in SCI and several other NDD, 
providing it with reasonable necessity to continue research on the topic. 
6. Improving the beneficial effect of protective autoimmunity 
Even though the positive effect of immunizing with NDP has rendered significant results, it 
is possible to potentiate this effect. The improvement of this strategy would yield a better 
functional recovery and, thereby, a better quality of life for NDD-affected individuals. It is 
clear that several damaging mechanisms take place during the acute phase of injury. 
Unfortunately, NDP-induced PA develops after a few days of immunization. Before PA sets 
in, the neural tissue is unprotected; therefore, the best approach is a combination of 
neuroprotective strategies. A therapeutic intervention tailored to each specific time point of 
injury pathophysiology. This approach will ameliorate one or more of the destructive events 
and may improve the functional outcome even more than PA alone. Excessive production of 
ROS from the beginning of CNS injury causes lipid peroxidation LP (Hall, 1994). 
Peroxidation of membrane lipids affects the integrity of the cell membrane and is the  
most damaging mechanism. The unregulated synthesis of free radicals offers a potential 
intervention route for the treatment of NDD. An example of this is the use of glutathione 
monoethyl ester (GSHE). This cell-permeant derivative of glutathione (GSH) is an  
www.intechopen.com
 
Neurodegenerative Diseases – Processes, Prevention, Protection and Monitoring 
 
532 
antioxidant that limits the effect of ROS on the bi-lipid membrane. GSH has shown 
neuroprotective properties after SCI (Guizar-Sahagun et al., 2005; Santoscoy et al., 2002). 
Aside from this effect, GSH supports the proliferation, growth, and differentiation of 
immune cells. Moreover, GSH is actually required for many specific T cell functions, 
including DNA replication and IL-2 synthesis (Kidd., 1997). The amount of GSH determines 
the magnitude of the immunological response (Droge et al., 1994) as well as its depletion 
inhibits normal function (Kidd, 1997). According to the data presented above, the addition 
of GSHE to NDP immunizations could significantly improve neuroprotection. The 
antioxidant properties of GSH will cover the overproduction of ROS from the beginning of 
injury while it could also assist in inducing a better PA response. A previous work carried 
out in our laboratory, examined the effect of this combination and demonstrated that the 
addition of GSHE to NDP immunizations induced earlier and better motor recovery after 
SCI compared to immunizations alone (Martinon et al., 2007). This effect was observed in 
animals subjected to either a contusive or a compressive SCI. The substantial improvement 
observed in treated animals allowed them to attain weight-supported plantar steps. This 
recovery is of great relevance when translating this treatment into a clinical setting. Motor 
improvement significantly correlated with increased axonal myelination as well as a marked 
survival of rubrospinal neurons. Besides finding adjuvant therapies for NDP-induced PA 
we wanted to see if multiple immunizations would increase the beneficial effect. We 
examined the effect of double immunizations and their effect on PA. Contrary to our 
expectations, double immunizations abolished the neuroprotective effect of single dose 
NDP-induced PA. The findings support the notion that the second immunization after SCI 
has a negative effect on PA. Rather than strengthening the protective effect, it eliminated it. 
This phenomenon was probably secondary to anergy since double immunization did not 
induce cell death (Martinon et al., 2007). According to the present data, the use of NDP and 
GSHE in SCI is a promising strategy. Further studies are necessary in order to establish the 
efficacy of this therapy and its potential applications into other NDD. Another attempt of 
synergistic therapeutic interventions is the use of GA with IFN-┚-1a in MS (Lublin & 
Reingold, 2001). The development of adjuvant and synergistic therapies will aid in the 
optimization of NDP-induced PA allowing us to tackle the pathophysiology of several NDD. 
7. Conclusion 
The concept of PA revolutionized the way we saw the immune system in several different 
diseases. We figured out that it was more important to modulate the response than to 
eliminate it. With the logarithmic explosion in knowledge we must now hold these 
conclusions. The use of NDP and their effect on the immune response have proven to be 
helpful in several different pathologies, particularly in NDD. Using the information that we 
have recollected across the years, the mechanisms through which NDP-induced PA exerts 
its effects is everyday less obscure. Unfortunately, due to hypersensitivity reactions and 
heterogeneous responses among patients NDP have not been taken to their maximum 
potential. Unfortunately, PA is developed under the bases that the immune system is 
healthy and will function normally following an insult to the CNS. However, MS is an 
autoimmune disease, a case where the immune system is fatally skewed. This paradox 
forces us to adopt a revolutionary idea such as PA and apply it to NDD. The application of 
NDP-induced PA to the field of NDD can yield insurmountable results and therefore we 
urge the scientific community to aid in continuing to shed light on these once obscure 
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mechanisms in order to make this therapeutic intervention efficacious and safe. The ultimate 
goal is to help the suffering and the complications of human disease. 
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